Expanding access through generics and biosimilars

Our Sandoz Division, a leading global generics company, plays an important role in Novartis efforts to increase access to affordable, high-quality medicines for patients worldwide. In 2021, Sandoz reached approximately 490 million patients with its portfolio of around 1 000 molecules across a wide range of disease areas.

Generics and biosimilars enable healthcare systems to improve access while containing spending growth. In the US, for example, generics accounted for 90% of the volume but only 18% of the cost of prescription medicines in 2020, according to research firm IQVIA.

Sandoz teams consider access in pricing strategies for all medicines, for example by typically entering the market well below the list price of the reference product, as well as taking local economic realities into account and acting to keep prices stable at times of market disruption – such as during the COVID-19 pandemic.

Our portfolio of generics and biosimilars increases the supply of affordable medicines across the income pyramid. They also provide the majority of products to our global health markets.

As one of the world’s largest suppliers of antibiotics, Sandoz also plays a central role in our efforts to tackle antimicrobial resistance. For more information, please see the section “Advancing our program to combat antimicrobial resistance.”